A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-334543 Given on a Daily Oral Regimen in Patients With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2012
At a glance
- Drugs Varlitinib (Primary)
- Indications Advanced breast cancer; Leukaemia; Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Array BioPharma
- 11 Apr 2011 Status changed from active, no longer recruiting to completed.
- 09 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Jan 2009 New source identified and integrated (Vanderbilt-Ingram Cancer Center).